Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669862 · ClinicalTrials.gov registry record · Phase 2
A Study of A-101 Solution in Subjects With Common Warts.
A Phase 2 study of Common Warts, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT02669862: Completed Phase 2 study of Common Warts, sponsored by Aclaris Therapeutics.
NCT02669862 is a Phase 2 study of Common Warts that has completed, run by Aclaris Therapeutics. The registered enrollment target is 98 participants, below the 125-participant average among 3 other Common Warts trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02669862, a Phase 2 study of Common Warts, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
Primary Outcome
The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate. Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.
Conditions Studied
Interventions
- DRUG A-101 Solution 40
- DRUG A-101 Solution 45
- DRUG Vehicle Solution
Study Locations (1)
Pennsylvania
- Aclaris Therapeutics, Inc. - Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-12-21 |
| Est. Completion | 2016-09-16 |
| Phase | Phase 2 |
What the finished NCT02669862 record still lists
NCT02669862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 125-participant average among 3 other Common Warts trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Common Warts appearing as the primary indexed condition, and to 3 interventions - of which A-101 Solution 40 is the first listed.
NCT02669862 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02669862 about?
NCT02669862 is a clinical study titled "A Study of A-101 Solution in Subjects With Common Warts.". This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
What is the current status of trial NCT02669862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2015-12-21. Estimated completion is 2016-09-16.
What conditions does trial NCT02669862 study?
This clinical trial studies the following conditions: Common Warts.
What interventions are being tested in trial NCT02669862?
The interventions under investigation include: A-101 Solution 40 (DRUG), A-101 Solution 45 (DRUG), Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT02669862?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02669862 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Warts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI